---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274319"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:29:01.198044+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma Q3 2025 net loss narrows to $7.0M; cash $48.7M; setrusumab data expected year-end

## Summary
- Net loss of $7.0M in Q3 2025 vs $15.0M in Q3 2024; operating loss of $10.0M.
- Cash and cash equivalents $48.7M as of Sep 30, 2025 (down from $69.8M Dec 31, 2024).
- R&D expenses rose to $4.3M (up $1.1M YoY) driven by setrusumab manufacturing and alvelestat Phase 3 prep.
- Phase 3 Orbit (p<0.039) and Cosmic (p<0.05) data for setrusumab in OI expected around end of 2025.
- Partnering discussions for alvelestat ongoing; vantictumab license to āshibio with retained EU rights.

## SEC filing metadata
- accession: 0001193125-25-274319
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312525274319/0001193125-25-274319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312525274319/mreo-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274319
- JSON: https://secwatch.observer/filing/0001193125-25-274319.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274319.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.